Sign inJoin waitlistJoin the waitlist

LS

Lale Shields

Director, Theranostic Clinical Research Trials · NYU Grossman School of Medicine

Credentials: · · · ·

History

Theranostic Clinical Research Trials · NYU Grossman School of Medicine
Present
NYU Grossman School of Medicine
Present

Endocrinology, Diabetes, and Metabolism
University of Virginia Medical Center
1994–1996
Memorial Sloan-Kettering Hospital
1993–1994
Nuclear Medicine
Memorial Sloan-Kettering Hospital
1989–1992
NYC Health and Hospitals Kings County Hospital
1986–1989
Ege University Faculty of Medicine
1982–1986

Research

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Journal of Clinical Oncology · 2014 · 1,268 citations
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Journal of Clinical Oncology · 2007 · 1,041 citations
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
Journal of Clinical Oncology · 2005 · 393 citations

SG
Stanley Goldsmith
28 papers
BC
Bruce Cheson
15 papers
John Leonard
15 papers
David Nanus
11 papers
Eric Genden
11 papers
MC
Morton Coleman
11 papers
PS
Peter Som
11 papers
SL
Steven Larson
11 papers
NB
Neil Bander
10 papers
JM
Josef Machac
9 papers
SH
Sherif Heiba
9 papers
BK
Brad Kahl
8 papers

Clinical trials

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Principal investigator · Terminated · Phase 1
Lale Kostakoglu
2014–2017
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Principal investigator · Unknown · Phase 2
Molecular Insight Pharmaceuticals, Inc.
2009–2021
Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2008–2014